logo
logo
PEN stock ticker logo

Penumbra, Inc.

NYSE•PEN
CEO: Mr. Adam Elsesser J.D.
Sector: Healthcare
Industry: Medical - Devices
Listing Date: 2015-09-18
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Contact Information
One Penumbra Place, Alameda, CA, 94502, United States
510-748-3200
www.penumbrainc.com
Market Cap
$12.81B
P/E (TTM)
72.0
29
Dividend Yield
--
52W High
$362.41
52W Low
$221.26
52W Range
75%
Rank28Top 16.1%
5.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$385.39M+0.00%
4-Quarter Trend

EPS

$1.21+0.00%
4-Quarter Trend

FCF

$68.05M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Revenue Growth 17.5% Total revenue reached $1.404 B USD in 2025, marking a 17.5% increase from the prior year's $1.195 B USD.
Profitability Surge Net income dramatically improved to $177.7 M USD in 2025, compared to only $14.0 M USD reported in 2024.
Margin Expansion Gross margin increased 3.9 percentage points to 67.1% in 2025, benefiting from favorable product mix and productivity.
Acquisition Agreement Signed Entered Merger Agreement in January 2026 to be acquired by Boston Scientific for approximately $14.5 B enterprise value.

Risk Factors

Merger Completion Uncertainty Closing the Boston Scientific Merger is subject to stockholder and regulatory approvals; failure could cause stock price decline.
Product Obsolescence Risk Success depends on anticipating technology advancements; delays in new product launches may impede market entry and sales generation.
Reimbursement Availability Risk Commercial success relies on adequate third-party reimbursement levels, which are subject to change and increasing cost containment pressures.
High Inventory Working Capital Maintaining high inventory levels, especially consignment coils, consumes significant working capital and risks obsolescence write-downs.

Outlook

Focus on Customer Penetration Future growth requires penetrating current customer base and expanding user base among specialist physicians in target end markets.
International Growth Investment Intent to grow internationally requires substantial spending to expand direct sales capabilities in new and existing geographic areas.
Continued R&D Investment Plan to continue substantial investments in developing innovative, proprietary products to maintain competitive advantage and efficacy.
Merger Expected Closing The acquisition by Boston Scientific is expected to close by the end of 2026, contingent upon customary closing conditions being met.

Peer Comparison

Revenue (TTM)

MOH stock ticker logoMOH
$45.08B
+7.7%
DVA stock ticker logoDVA
$13.64B
+6.5%
HSIC stock ticker logoHSIC
$13.18B
+4.0%

Gross Margin (Latest Quarter)

HQY stock ticker logoHQY
92.4%
+6.3pp
GMED stock ticker logoGMED
72.0%
+6.5pp
HIMS stock ticker logoHIMS
71.9%
-5.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
PEN$12.81B72.013.4%12.0%
ALGN$12.61B29.210.7%1.3%
GMED$12.20B22.712.4%2.2%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
5.9%
Steady Growth
4Q Net Income CAGR
6.5%
Profitability Improving
Cash Flow Stability
100%
Strong Cash Flow

Deep Research

Next earnings:May 6, 2026
|
EPS:$1.06
|
Revenue:$371.27M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data